Literature DB >> 8935729

Loss of antimicrobial susceptibility in aerobic gram-negative bacilli repeatedly isolated from patients in intensive-care units.

F A Manian1, L Meyer, J Jenne, A Owen, T Taff.   

Abstract

OBJECTIVE: To study the loss of antimicrobial susceptibility in repeat (same patient, same bacterial species, and same site) aerobic gram-negative bacilli (AGNB) isolated from individual patients during their stay in the intensive-care unit (ICU).
SETTING: A 792-bed, tertiary-care community hospital with a total of 107 adult, pediatric, and neonatal ICU beds.
METHOD: An observational prospective study performed November 1992 through mid-July 1993.
RESULTS: Of 594 consecutive AGNB from 287 ICU patients, 117 isolates (20%) from 55 patients (19%) were repeat isolates, with the majority obtained from respiratory secretions (83%). Pseudomonas aeruginosa and Enterobacter species accounted for 61% of the isolates. Forty-two (36%) of the repeat isolates from 24 patients (44%) had > or = 4-fold increase in minimum inhibitory concentration to at least one antibiotic and no longer were considered fully susceptible based on National Committee on Clinical Laboratory Standards criteria. Loss of antimicrobial susceptibility often developed within several (median 8) days and was associated only infrequently with simultaneous transition from colonization to infection in the individual patient. Use of certain beta-lactam antibiotics was associated with increasing resistance to several other antibiotics in the same class. Concurrent use of beta-lactams and aminoglycosides did not prevent loss of antimicrobial susceptibility to the former in repeat isolates.
CONCLUSION: We conclude that loss of antimicrobial susceptibility in repeat AGNB isolated from ICU patients is common, usually is not associated with transition from colonization to infection, and often is associated with prior use of antibiotics. Minimizing antibiotic use in ICU patients should help reduce the risk of antimicrobial resistance in repeat AGNB isolates.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8935729     DOI: 10.1086/647284

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  7 in total

1.  Molecular epidemiology of an outbreak of multidrug-resistant Enterobacter aerogenes infections and in vivo emergence of imipenem resistance.

Authors:  Y De Gheldre; N Maes; F Rost; R De Ryck; P Clevenbergh; J L Vincent; M J Struelens
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

Review 2.  Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis.

Authors:  Mical Paul; Adi Lador; Simona Grozinsky-Glasberg; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2014-01-07

3.  Emergence of multidrug resistance in ubiquitous and dominant Pseudomonas aeruginosa serogroup O:11. The Greek Pseudomonas Aeruginosa Study Group.

Authors:  P T Tassios; V Gennimata; A N Maniatis; C Fock; N J Legakis
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

Review 4.  Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.

Authors:  M Denton; K G Kerr
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

5.  Molecular epidemiology of Stenotrophomonas maltophilia isolated from clinical specimens from patients with cystic fibrosis and associated environmental samples.

Authors:  M Denton; N J Todd; K G Kerr; P M Hawkey; J M Littlewood
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

6.  Isolate removal methods and methicillin-resistant Staphylococcus aureus surveillance.

Authors:  Fenfang Li; Tracy L Ayers; Sarah Y Park; F DeWolfe Miller; Ralph MacFadden; Michele Nakata; Myra Ching Lee; Paul V Effler
Journal:  Emerg Infect Dis       Date:  2005-10       Impact factor: 6.883

7.  Mechanisms of antimicrobial resistance in Gram-negative bacilli.

Authors:  Étienne Ruppé; Paul-Louis Woerther; François Barbier
Journal:  Ann Intensive Care       Date:  2015-08-12       Impact factor: 6.925

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.